Pfizer, Mylan strengthen ties, create new company
July 29, 2019 by Linda A. Johnson The Associated Press
July 29, 2019 – Pfizer, the U.S.’s largest drugmaker, is creating a hybrid new drug company by combining its off-patent branded drug business with the generic pharmaceutical company Mylan.
The two companies said Monday that they’ll ultimately spin off the combination of Mylan, a $10 billion company, with Pfizer’s Upjohn, which sells one-time blockbusters like Viagra and Lipitor that have lost patent protection.
The complex deal, expected to close in the middle of next year, will create a company with estimated 2020 revenue in excess of $19 billion, with sales in more than 165 countries. The name for the new company has yet to be determined.
The two companies have worked together for years. Pfizer manufactures Mylan’s EpiPen, an auto-injector used to halt life-threatening allergic reactions. Mylan was heavily criticized, and its CEO Heather Bresch was brought before U.S. Congress two years ago, to answer questions about the price of the EpiPen, which had jumped five-fold to $600 for two EpiPens.
They have been in short supply for more than a year because of quality problems and upgrades at a Pfizer factory.
Upjohn, the name of one of the companies Pfizer gobbled up during a spate of acquisitions in the 1990s and 2000s, sells off-patent and generic drugs that include the stars that drove Pfizer’s growth: pain killers Celebrex and Lyrica, Norvasc for high blood pressure, Effexor for depression, Xanax for anxiety and Zoloft for depression.
The strengthening ties between Pfizer and Mylan come at a precarious time for big drugmakers, who face enormous pressure to cut high prices for brand-name drugs. Also, Pfizer just got generic competition to one of its biggers sellers, Lyrica.
Likewise, years of pressure from wholesalers to reduce prices for generic drugs, which comprise most of Mylan’s portfolio, have crimped its profits and driven its share price down 50 per cent in the past year.
That enabled Pfizer to “combine businesses at a more attractive price,” Edward Jones analyst Ashtyn Evans said, adding that Pfizer has wanted to become a smaller, more innovative company and now has a strong pipeline of experimental new drugs.
“Growth from new, innovative products will have a bigger impact,” she said, “growing off a smaller base.”
Pfizer Inc. investors will be getting shares in the new company tax free – and that entity will be offering a dividend as well.
Shareholders of Pfizer will receive 0.12 share of the new company for each Pfizer share they hold and will own 57 per cent of the combined new company; Mylan shareholders will own 43 per cent, receiving one share of the new company for each of their Mylan shares.
Mylan shares jumped 14 per cent to $21.02 in early trading. Pfizer shares, down from a $46 high late last year, dipped $1.08, or 2.5 per cent, to $42.01.
The new company will be incorporated in Delaware and run operations in Pittsburgh, Hyderabad, India, and Shanghai, Upjohn’s current base.
Mylan, which had moved its legal location from Pennsylvania to Hertfordshire, England, will legally move back to the U.S. Pfizer is based in New York. Pfizer spent several years unsuccessfully trying to drugmakers based in lower-tax European countries so it could move there on paper and reduce its U.S. tax bill, finally giving up after the U.S. tax overhaul last year changed the economics of such a manoeuvre.
The new company will be run Michael Goettler, now head of Upjohn, and will have Mylan’s current board chairman, Robert Coury as its executive chairman. Bresch, the Mylan CEO, will retire when the deal closes.
Upjohn currently brings in roughly 23 per cent of Pfizer’s total sales, which amounted to $53.6 billion last year.
Upjohn will issue $12 billion of debt at or prior to separation, with gross debt proceeds kept by Pfizer. The new company will have about $24.5 billion of total debt outstanding at closing.